BDX - Becton Dickinson up 4% after raising FY 2022 guidance strong FQ1 results

Shares of Becton, Dickinson (BDX +4.4%) are up in morning trading after the company raised its FY 2022 guidance. Becton, Dickinson now expects adjusted diluted EPS for the fiscal year to be between $12.80 and $13.00, compared to $12.30-$12.50 before. The company also had an extremely strong FQ1 2022, beating  Street estimates on both the top and bottom lines. It was able to do so even as revenue declined 6% year over year to ~$5B. The major revenue loss for the quarter was in the company's life sciences business, which includes integrated diagnostic solutions and biosciences. Revenue declined 25% to $1.5B. The medical and interventional units both had modest single-digit percentage increases in revenue. Becton, Dickinson ended the year with $1.9B in cash. Check out why Seeking Alpha contributor Cappuccino Finance considers Becton, Dickinson a buy.

For further details see:

Becton, Dickinson up 4% after raising FY 2022 guidance, strong FQ1 results